RecruitMe Clinical Trial
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
A study for patients with myelofibrosis (bone marrow disorder) using study drug INCB050465
| Sponsor: | Incyte Corporation |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR0403 |
| U.S. Government ID: | NCT02718300 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this research study is to determine the effects of INCB050465 in combination with ruxolitinib treatment on spleen size and/or symptoms and to learn about any of the side effects that might occur during or following dosing with this combination of molecules in patients diagnosed with myelofibrosis.
